A Study to Evaluate the Appropriateness of the Voriconazole Dosing Regimen
NCT ID: NCT03760276
Last Updated: 2018-11-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
11 participants
INTERVENTIONAL
2018-08-20
2018-10-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Voriconazole TBD mg tablet orally, every 12 hours for 7 days
Voriconazole Oral Product (Vfend®)
To be determined mg of Voriconazole (Vfend®, anti-fungal agent)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Voriconazole Oral Product (Vfend®)
To be determined mg of Voriconazole (Vfend®, anti-fungal agent)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Healthy Korean male and female volunteers aged 20 to 45
* Those with a body weight of 50 kg or more and less than 90 kg and a body mass index (BMI) of 18 or more and less than 27 (BMI(kg/m2) = body weight (kg)/{height(m)}2
* CYP2C19 EM or PM
Exclusion Criteria
* Subjects with a history of gastrointestinal disorders (Crohn's disease, ulcers, acute or chronic pancreatitis, etc.) or gastrointestinal surgery (excluding simple cecal surgery or hernia surgery) that may affect the absorption of the test drug
* Those with a history of substance abuse within the last 2 months
* Those who have taken any prescribed medicines or herbal medicines within 2 weeks prior to the date of the first medicines, or those taking any general medicines (OTC) or vitamin preparations (eligible if the other conditions are reasonable according to the judgment of the investigator)
* Those who donate blood within 30 days before the date of the first dose or who have participated in the clinical study of other clinical trial drugs or marketed drugs within 3 months
* Those who have had significant adverse reactions such as hypersensitivity reactions to azole drugs including drugs for clinical research
* Those who are not planning on or planning to have a pregnancy during the trial and are not able to use a recognized method of contraception (eg, sterilization surgery of the person and partner, intrauterine contraceptive device, or diaphragm contraception (such as diaphragm or condom use)
* Persons who are continuously drinking (21 units / week, 1 unit = 10 g of pure alcohol) or who can not abstain from 3 days before the first dose to the end of the clinical trial
* Those who smoked more than 10 cigarettes per day for the last 3 months or who can not quit smoking 3 days before the first dose
* Those who consume grapefruit / caffeine-containing food within 3 days of the first dose or who cannot be prohibited during the clinical study period
* Screening tests for urine pregnancy (β-hCG) positive or lactating women
* Those with genetic problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption.
* A person who is found to be unsuitable for participation in clinical research due to safety laboratory results or other reasons
20 Years
45 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Seoul National University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
SeungHwan Lee
Clinical Assistant Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Seoul National University Hospital Clinical Trial Center
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Voriconazole_CYP2C19
Identifier Type: -
Identifier Source: org_study_id